Wu Connie M, Wu Annie M, Greenberg Paul B, Yu Fei, Lum Flora, Coleman Anne L
Ophthalmic Surg Lasers Imaging Retina. 2018 Apr 1;49(4):241-244. doi: 10.3928/23258160-20180329-05.
To describe the frequency and variation of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) use for diabetic macular edema (DME) in the United States.
The authors obtained a 5% sample of Medicare beneficiaries from the Medicare Part B claims files from 2010 to 2013 and identified beneficiaries with DME using the ICD-9-CM code (362.07). Geographic variation was examined by comparing injection frequencies of bevacizumab and ranibizumab across U.S. census divisions using Chi-squared analysis.
The sample included 5,290 Medicare beneficiaries with DME. Overall, there was greater bevacizumab use (86.4%) compared to ranibizumab use (13.6%). Frequency of bevacizumab use was highest in the Mountain division (92.2%) and lowest in the Mid-Atlantic (76.0%). The total number of bevacizumab and ranibizumab injections for DME varied significantly between U.S. census divisions (P < .0001).
Bevacizumab is used more frequently than ranibizumab for the treatment of DME among Medicare beneficiaries, with significant geographic variation. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:241-244.].
描述美国玻璃体内注射贝伐单抗（阿瓦斯汀；基因泰克公司，加利福尼亚州南旧金山）和雷珠单抗（兰尼单抗；基因泰克公司，加利福尼亚州南旧金山）治疗糖尿病性黄斑水肿（DME）的频率及差异。
作者从2010年至2013年医疗保险B部分理赔档案中获取了5%的医疗保险受益人的样本，并使用ICD-9-CM编码（362.07）识别出患有DME的受益人。通过使用卡方分析比较美国各人口普查分区贝伐单抗和雷珠单抗的注射频率来研究地理差异。
该样本包括5290名患有DME的医疗保险受益人。总体而言，与雷珠单抗的使用（13.6%）相比，贝伐单抗的使用更为广泛（86.4%）。贝伐单抗的使用频率在山区最高（92.2%），在大西洋中部最低（76.0%）。美国各人口普查分区用于DME的贝伐单抗和雷珠单抗注射总数存在显著差异（P <.0001）。
在医疗保险受益人中，贝伐单抗用于治疗DME的频率高于雷珠单抗，且存在显著的地理差异。[《眼科手术、激光与视网膜成像》。2018；49：241 - 244。]
